Shining a light in the black box of orphan drug pricing

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Picavet, Eline ^a   Morel, Thomas ^a   Cassiman, David ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Orphan drugs; Price setting; Pricing

Indexed keywords

ALIPOGENE TIPARVOVEC; BROMELAIN; HYDROXYUREA; IVACAFTOR; ORPHAN DRUG; SAPROPTERIN; TEDUGLUTIDE;

ARTICLE; BELGIUM; COST EFFECTIVENESS ANALYSIS; CZECH REPUBLIC; DRUG COST; FRANCE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HOSPITAL PURCHASING; HUMAN; ITALY; LONG TERM CARE; NETHERLANDS; OVERALL SURVIVAL; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT DURATION; UNITED KINGDOM;

DRUG COSTS; ORPHAN DRUG PRODUCTION;

EID: 84900800675     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-62     Document Type: Article

References (56)

1. Orphan drug development: an economically viable strategy for biopharma R & D. Meekings KN, Williams CS, Arrowsmith JE, Drug Discov Today 2012 17 660 664 10.1016/j.drudis.2012.02.005 22366309
2. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O, Zhou Y, Health Pol 2010 95 216 228 10.1016/j.healthpol.2009.12.001
3. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, J Med Econ 2010 13 295 301 10.3111/13696998.2010.491427 20482245
4. Estimating the budget impact of orphan medicines in Europe: 2. Schey C, Milanova T, Hutchings A, Orphanet J Rare Dis 2011 6 62 10.1186/1750-1172-6-62 21951518
5. Access to orphan drugs in Europe: current and future issues. Michel M, Toumi M, Expert Rev Pharmacoecon Outcomes Res 2012 12 23 29 10.1586/erp.11.95 22280193
6. Orphan drug pricing may warrant a competition law investigation. Roos JC, Hyry HI, Cox TM, BMJ 2010 341 6471 10.1136/bmj.c6471 21081598
7. Pricing and reimbursement of orphan drugs: the need for more transparency. Simoens S, Orphanet J Rare Dis 2011 6 42 10.1186/1750-1172-6-42 21682893
8. Orphan drugs. Messori A, Cicchetti A, Patregani L, BMJ 2010 341 4615 10.1136/bmj.c4615 20736283
9. Sustainable rare diseases business and drug access: no time for misconceptions. Rollet P, Lemoine A, Dunoyer M, Orphanet J Rare Dis 2013 8 109 10.1186/1750-1172-8-109 23879976
10. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino J, Soto J, Casado MA, Oyaguez I, Appl Health Econ Health Pol 2010 8 301 315 10.2165/11531880-000000000-00000
11. Quantitative Analysis of the Influence of Disease and Product Characteristics on Orphan Drug Prices in Europe [abstract]. Aballea S, Toumi M, Vataire AL, Millier A, Lamure M, Value Health 2010 13 82
12. Study on Orphan Drugs-Phase I Overview of the Conditions for Marketing Orphan drugs in Europe. Alcimed, [ http://ec.europa.eu/health/files/orphanmp/ doc/pricestudy/final-final-report-part-1-web-en.pdf ]
13. A comparative study of European rare disease and orphan drug markets. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, Health Pol 2010 97 173 179 10.1016/j.healthpol.2010.05.017
14. European Medicines Agency. [ http://www.ema.europa.eu/ ]
15. The weight of nations: an estimation of adult human biomass. Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I, BMC Public Health 2012 12 439 10.1186/1471-2458-12-439 22709383
16. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. World Health Organisation, [ http://www.who.int/childgrowth/ standards/technical-report/en/ ]
17. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. Haycock GB, Schwartz GJ, Wisotsky DH, J Pediatr 1978 93 62 66 10.1016/S0022-3476(78)80601-5 650346 (Pubitemid 8351870)
18. XE The World's Favorite Currency Site. [ http://www.xe.com/ ]
19. Eurostat. European Commission, [ http://epp.eurostat.ec.europa.eu/portal/ page/portal/eurostat/home/ ]
20. Beleid voor zeldzame ziekten en Weesgeneesmiddelen KCE reports 112A. Denis A, Simoens S, Fostier C, Mergaert L, Cleemput I, [ https://kce.fgov.be/ sites/default/files/page-documents/d20091027330.pdf ]
21. BCFI-Belgian Centre for Pharmacotherapeutic Information. [ http://www.bcfi.be/ ]
22. Medicijnkosten. College voor Zorgverzekeringen, [ http://www. medicijnkosten.nl/ ]
23. SÚKL-State Institute for Drug Control. [ http://www.sukl.eu/ ]
24. Thériaque. [ http://www.theriaque.org/ ]
25. Informazioni sui farmaci. [ http://www.informazionisuifarmaci.it/ ]
26. AIFA-Agenzia Italiana del Farmaco. [ http://www.agenziafarmaco.gov.it/ ]
27. Royal Pharmaceutical Society, British Medical Association, British National Formulary 65 London: Elsevier Inc 2013
28. Reimbursement of Drugs-Performance of Governmental Management. Belgian Treasury, [ https://www.ccrek.be/Docs/2014-02-TerugbetalingGeneesmiddelen.pdf ]
29. Do ultra-orphan medicinal products warrant ultra-high prices? A review. Picavet E, Cassiman D, Simoens S, Orphan Drugs Res Rev 2013 3 23 31
30. What is wrong with orphan drug policies? Cote A, Keating B, Value Health 2012 15 1185 1191 10.1016/j.jval.2012.09.004 23244823
31. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Schlander M, Beck M, Curr Med Res Opin 2009 25 1285 1293 10.1185/03007990902892633 19366306
32. Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? Hemphill TA, J Bus Ethics 2010 94 225 242 10.1007/s10551-009-0259-x
33. ISPOR short course: Elements of Pharmaceutical/Biotech Pricing. Mycka JM, Dellamano R, Proceedings of the ISPOR 13th Annual European Congress (November 6-9, 2010, Prague, Czech Republic). 2010
34. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Hughes-Wilson W, Palma A, Schuurman A, Simoens S, Orphanet J Rare Dis 2012 7 74 10.1186/1750-1172-7-74 23013790
35. Drugs for rare diseases: influence of orphan designation status on price. Picavet E, Dooms M, Cassiman D, Simoens S, Appl Health Econ Health Policy 2011 9 275 279 10.2165/11590170-000000000-00000 21682354
36. What is wrong with orphan drug policies? Suggestions for ways forward. Kanavos P, Nicod E, Value Health 2012 15 1182 1184 10.1016/j.jval.2012.08.2202 23244822
37. FDA Application: Search Orphan Drug Designations and Approvals. U.S. Food and Drug Administration, [ http://www.accessdata.fda.gov/scripts/opdlisting/ oopd/ ]
38. What Price do we pay for Repurposing Medicines for Rare Diseases? Simoens S, Picavet E, Cassiman D, Dooms M, Value Health 2012 15 15 A16
39. OneSource. [ http://www.onesource.com/ ]
40. Health Systems in Transition (HiT) series. European Observatory on Health Systems and Policies, [ http://www.euro.who.int/en/about-us/partners/ observatory/health-systems-in-transition-hit-series ]
41. Pharmaceutical Pricing and Reimbursement Information (PPRI) Report. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, [ http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/PPRI-Report-final. pdf ]
42. Martikainen J, Rajaniemi S, Drug reimbursement systems in EU Member States, Iceland and Norway Helsinki: Belgian Health Care Knowledge Centre 2002
43. Market uptake of orphan drugs-a European analysis. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S, J Clin Pharm Ther 2012 37 664 667 10.1111/j.1365-2710.2012.01364.x 22731105
44. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: A comparative study of managed entry agreements across seven European countries. Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, Simoens S, Orphanet J Rare Dis 2013 8 198 10.1186/1750-1172-8-198 24365263
45. Issues surrounding orphan disease and orphan drug policies in Europe. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, Appl Health Econ Health Pol 2010 8 343 350 10.2165/11536990-000000000-00000
46. Impact of Indication Extensions on Pharmaceutical Prices [abstract]. Genane C, Marinoni G, Reinaud F, Ando G, Value Health 2013 16 455
47. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Miyamoto BE, Kakkis ED, Orphanet J Rare Dis 2011 6 49 10.1186/1750-1172-6-49 21733145
48. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. European Commission, Off J Eur Communities 2000 L 18 1 5
49. Tiger in the Fiscal Room: Beware the Increasing Cost and Number of Orphan Drugs. Silverman E, 2013 [ http://www.managedcaremag.com/archives/1303/1303. orphandrugs.html ]
50. Reforming the payment system for medical oncology. Bach PB, JAMA 2013 310 261 262 10.1001/jama.2013.8127 23817729
51. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Linley WG, Hughes DA, Health Econ 2013 22 948 964 10.1002/hec.2872 22961976
52. The World's Most Expensive Drug. Herper M, [ http://www.forbes.com/2010/ 02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html ]
53. A pilot study of multicriteria decision analysis for valuing orphan medicines. Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A, Value Health 2013 16 1163 1169 10.1016/j.jval.2013.10.002 24326170
54. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ, Clin Ther 2010 32 1651 1661 10.1016/j.clinthera.2010.08.006 20974323
55. Differential pricing of new pharmaceuticals in lower income European countries. Kalo Z, Annemans L, Garrison LP, Expert Rev Pharmacoecon Outcomes Res 2013 13 735 741 10.1586/14737167.2013.847367 24219049
56. Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCa-OMP): Transparent Value Framework. [ http://ec.europa.eu/ enterprise/sectors/healthcare/files/docs/orphans-framework-en.pdf ]